TELA Bio will report third quarter 2025 financial results on November 13, 2025, with a conference call scheduled.
Quiver AI Summary
TELA Bio, Inc., a medical technology company specializing in soft-tissue reconstruction solutions, announced that it will release its third quarter 2025 financial results on November 13, 2025. Following the results, the management will host a conference call and webcast at 4:30 p.m. ET to discuss the financials and provide a corporate update. Interested investors can register online to participate in the call, and a live webcast will be available on the company's website. TELA Bio aims to enhance clinical outcomes by leveraging innovative technologies that support the restoration of patients' anatomy while minimizing reliance on synthetic materials. The press release includes forward-looking statements which carry inherent risks and uncertainties, urging investors to review relevant filings for additional context.
Potential Positives
- TELA Bio will report its third quarter 2025 financial results, indicating ongoing communication with investors and transparency in financial performance.
- The scheduled conference call and webcast reflect the company's commitment to engaging with stakeholders and providing corporate updates.
- The company emphasizes its focus on innovative soft-tissue reconstruction solutions, which highlights its dedication to advancing medical technologies and improving surgical outcomes.
Potential Negatives
- Uncertainty surrounding future performance is emphasized, warning that actual results may differ materially from expectations due to various risks and uncertainties.
- The press release does not provide any concrete financial projections or highlights from the upcoming earnings report, which may raise concerns among investors looking for positive indicators.
- The requirement for participants to register in advance for the earnings call may limit real-time investor engagement and feedback opportunities during the call.
FAQ
When will TELA Bio report its third quarter 2025 financial results?
TELA Bio will report its third quarter 2025 financial results on November 13, 2025.
What time is TELA Bio's earnings conference call?
The earnings conference call will be held at 4:30 p.m. ET on November 13, 2025.
How can I listen to TELA Bio's conference call?
Interested investors can register online and access the webcast via TELA's Events & Presentations page.
What is TELA Bio's focus as a medical technology company?
TELA Bio focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes and utilize the patient's own anatomy.
Where can I find more information about TELA Bio?
More information about TELA Bio can be found on their official website at www.telabio.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TELA Hedge Fund Activity
We have seen 17 institutional investors add shares of $TELA stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AIGH CAPITAL MANAGEMENT LLC removed 1,416,323 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,747,666
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,233,623 shares (+31.8%) to their portfolio in Q2 2025, for an estimated $2,393,228
- MINK BROOK ASSET MANAGEMENT LLC removed 357,092 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $692,758
- PENTWATER CAPITAL MANAGEMENT LP removed 183,755 shares (-18.4%) from their portfolio in Q2 2025, for an estimated $356,484
- RENAISSANCE TECHNOLOGIES LLC removed 177,111 shares (-72.5%) from their portfolio in Q2 2025, for an estimated $343,595
- HBK SORCE ADVISORY LLC added 100,365 shares (+inf%) to their portfolio in Q3 2025, for an estimated $149,543
- UBS GROUP AG removed 85,135 shares (-25.7%) from their portfolio in Q2 2025, for an estimated $165,161
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Third Quarter Earnings Conference Call and Webcast Details
Investors interested in listening to the conference call should
register online
. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the
Events & Presentations
page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit
www.telabio.com
.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at
www.sec.gov
,
including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
[email protected]